Outcome in 203 patients (PTS) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX): Retreatment with fludarabine (FLU).

被引：0
|
作者：
Thomas, D [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, FJ [1 ]
Lerner, S [1 ]
Keating, MJ [1 ]
机构：
[1] Univ Texas, Md Anderson Canc Ctr, Leukemia Sect, Houston, TX USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
419
引用
收藏
页码：102A / 103A
页数：2
相关论文
共 50 条
  • [31] Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
    Meacham, Philip J.
    Williams, AnnaLynn M.
    Strawderman, Myla
    Baran, Andrea M.
    Archibald, William J.
    Wallace, Danielle S.
    Tschernia, Nicholas P.
    Burack, Walter Richard
    Barr, Paul M.
    Zent, Clive S.
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1636 - 1644
  • [32] Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy
    Brian McLaughlin
    Annie Im
    Anastasios Raptis
    Mounzer Agha
    Jing-Zhou Hou
    Robert Redner
    Shrina Duggal
    Yan Lin
    Clay Smith
    Michael Boyiadzis
    International Journal of Hematology, 2012, 96 : 743 - 747
  • [33] Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy
    McLaughlin, Brian
    Im, Annie
    Raptis, Anastasios
    Agha, Mounzer
    Hou, Jing-Zhou
    Redner, Robert
    Duggal, Shrina
    Lin, Yan
    Smith, Clay
    Boyiadzis, Michael
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (06) : 743 - 747
  • [34] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 110A - 110A
  • [35] Second malignancies in B-cell chronic lymphocytic leukemia (CLL): Association with CLL but no additional impact with fludarabine or alkylator treatment.
    Flynn, JM
    Howard, RS
    Byrd, JC
    BLOOD, 1999, 94 (10) : 298B - 298B
  • [36] Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
    Huhn, D
    von Schilling, C
    Wilhelm, M
    Ho, AD
    Hallek, M
    Kuse, R
    Knauf, W
    Riedel, U
    Hinke, A
    Srock, S
    Serke, S
    Peschel, C
    Emmerich, B
    BLOOD, 2001, 98 (05) : 1326 - 1331
  • [37] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
  • [38] A phase II study of denileukin diftitox (ONTAKR) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.
    Kuriakose, P
    Turturro, F
    Berdeja, JG
    Kerr, R
    Surendranathan, A
    Black, J
    Frankel, AE
    BLOOD, 2004, 104 (11) : 289B - 289B
  • [39] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [40] A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.
    Lilly, M
    Kuriakose, P
    Turturro, F
    Berdeja, J
    Kerr, R
    Surendranathan, A
    Black, J
    Frankel, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 597S - 597S
12345